Skip to main content

Advertisement

SpringerLink
Log in

Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma

  • Brief Report
  • Phase III Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Fourteen patients with advanced renal cell carcinoma were treated on a phase II trial with liposomal encapsulated doxorubicin (Lipodox, LED). None of the fourteen evaluable patients achieved a complete or partial response. Myelosuppression was the most common toxicity and no cardiac toxicity was evident. Seventynine percent (11 of 14) of patients experienced grade III or IV neutropenia. In summary, LED did not show antitumor activity in the treatment of advanced renal cell carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fojo AT, Shen D-W, Mickley LA, Pastan I, Gottesman MM: Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 5:1922–1927, 1987

    Google Scholar 

  2. Thierry AR, Vige D, Dritschilo A, Rahman A: Modulation of multidrug resistance by liposomally encapsulated doxorubicin in two human MDS tumor cell lines. Proc Am Assoc Cancer Res 32:373, 1991

    Google Scholar 

  3. Oudard S, Thierry A, Jorgensen TJ, Rahman A: Sensitization of multidrug resistant colon cancer cells to doxorubicin encapsulated in liposomes. Cancer Chemother Pharmacol 28:259–265, 1991

    Google Scholar 

  4. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981

    Google Scholar 

  5. Rahman A, Treat J, Roh J-K, Potkul LA, Alvord WG, Forst D, Woolley PV: A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 8:1093–1100, 1990

    Google Scholar 

  6. Treat J, Greenspan A, Forst D, Sanchez JA, Ferrans VJ, Potkul LA, Woolley PV, Rahman R: Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J Natl Cancer Inst 82:1706–1710, 1990

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York

    Teresa Murray Law, Peter Mencel & Robert J. Motzer

Authors
  1. Teresa Murray Law
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Mencel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert J. Motzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Law, T.M., Mencel, P. & Motzer, R.J. Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma. Invest New Drugs 12, 323–325 (1994). https://doi.org/10.1007/BF00873048

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00873048

Key words

Search

Navigation